Menu
← Oncology Approval Tracker
FDA DECISION ·
Tafinlar + Mekinist
dabrafenib + trametinib · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults and children aged one year or older with BRAF V600E-mutant unresectable or metastatic solid tumors after progression on previous therapy and with no satisfactory alternative. The action lowered the age threshold from six years. It excludes colorectal cancer under this indication.
LAMPGEN ANALYSIS
Why it matters
This supplement expanded the tumor-agnostic BRAF-directed regimen to younger children.
What research teams should watch
Record age and tumor histology and distinguish the tumor-agnostic criteria from the separate low-grade glioma label.
PRIMARY RECORDS